Advances in management of chronic metabolic acidosis in chronic kidney disease

Research output: Contribution to journalReview articlepeer-review

8 Scopus citations


Purpose of reviewChronic metabolic acidosis is a common complication of chronic kidney disease (CKD) and is associated with adverse consequences, such as CKD progression and muscle wasting. We review the findings from recent clinical trials that have examined the effects of sodium bicarbonate therapy and veverimer in patients with CKD and chronic metabolic acidosis.Recent findingsThere are four recent clinical trials on chronic metabolic acidosis of CKD. In a pilot, cross-over study, 6 weeks of sodium bicarbonate therapy improved vascular endothelial function, measured by brachial artery flow-mediated dilation. In a single-center, randomized, open-label study, 6 months of sodium bicarbonate therapy increased muscle mass and lean body mass, and preserved kidney function. The other two clinical trials (phase 1/2 and phase 3 studies) examined the effects of veverimer, which is a hydrochloric acid binder. The phase 3 study showed that 12-weeks of veverimer increased serum bicarbonate levels and might improve physical function. The effects of veverimer on CKD progression, physical function and cardiovascular endpoints as well as its long-term safety are yet to be determined.SummaryRecent studies suggest that sodium bicarbonate therapy may improve vascular endothelial function and muscle mass, and preserve renal function. Veverimer increases serum bicarbonate level and could be a potential new therapeutic option for treating chronic metabolic acidosis.

Original languageEnglish (US)
Pages (from-to)409-416
Number of pages8
JournalCurrent opinion in nephrology and hypertension
Issue number5
StatePublished - Sep 1 2019


  • alkali therapy
  • chronic metabolic acidosis
  • hydrochloric acid binder
  • sodium bicarbonate therapy
  • veverimer

ASJC Scopus subject areas

  • Internal Medicine
  • Nephrology


Dive into the research topics of 'Advances in management of chronic metabolic acidosis in chronic kidney disease'. Together they form a unique fingerprint.

Cite this